MyMD Pharmaceuticals is a clinical stage pharmaceutical company committed to extending healthy lifespan. Currently, we are developing through the FDA approval process and expect to commercialize two therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD.
MyMD, Inc. (NASDAQ: AKER) seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming events and presentations and financial documents. Prior to the merger with AKER, the company traded on the Nasdaq under the ticker symbol AKER.